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Abstract
Although autism has a clear genetic component, the high genetic heterogeneity of the disorder has been a challenge for
the identification of causative genes. We used homozygosity analysis to identify probands from nonconsanguineous
families that showed evidence of distant shared ancestry, suggesting potentially recessive mutations. Whole-exome
sequencing of 16 probands revealed validated homozygous, potentially pathogenic recessive mutations that segregated
perfectly with disease in 4/16 families. The candidate genes (UBE3B, CLTCL1, NCKAP5L, ZNF18) encode proteins involved in
proteolysis, GTPase-mediated signaling, cytoskeletal organization, and other pathways. Furthermore, neuronal depolariza-
tion regulated the transcription of these genes, suggesting potential activity-dependent roles in neurons. We present a
multidimensional strategy for filtering whole-exome sequence data to find candidate recessive mutations in autism, which
may have broader applicability to other complex, heterogeneous disorders.
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Introduction
Autism is a neurodevelopmental disorder characterized by
impaired communication skills, social behavior abnormalities, and
stereotypies, with a prevalence of ,1/150 children [1]. It is
considered to be one of the most highly genetic neuropsychiatric
disorders with a heritability of 40–80% [2,3]. Family studies show
that siblings of autistic children are at a ,25-fold higher risk to
develop autism than the general population [4], and twin studies
show concordance of the autism phenotype in 20–30% of
dizygotic twins and ,60% of monozygotic twins [3,4]. Genome-
wide linkage and association studies, and candidate gene
approaches have identified several susceptibility loci and impli-
cated potential autism genes [5–7]. The fact that no single genetic
aberration accounts for more than 1% of cases suggests extreme
genetic heterogeneity [8,9], posing a major challenge to identifying
causative genes. To date genes have been identified on the basis of
overlap with other syndromic neurodevelopmental disorders (e.g.
Fragile X syndrome, Angelman syndrome, Rett syndrome),
chromosomal abnormalities and copy number variation, and as
causes for nonsyndromic autism (e.g. NRXN1, NLGN3/4X,
SHANK3) [4,10]. In a few cases, autism has been shown to be
caused by homozygous recessive mutations due to recent shared
ancestry [11], although the contribution of recessive mutations in
outbred populations remains unexplored.
Recessive mutations in autism may behave like other rare
recessive traits, thus allowing gene mapping using homozygosity
analysis. Homozygosity mapping is frequently employed to isolate
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disease genes in families where the parents are known to be
definably related, typically as cousins, which increases the risk for
recessive disease [12–14]. However homozygous recessive ‘‘found-
er’’ mutations are also common in patients whose parents share
only distant ancestry, common ethnicity, or in some cases no
apparent ancestry at all [15], and population analysis of runs of
homozygosity has been used to define genomic loci that may
harbor such mutations in diseases characterized by genetic
heterogeneity [16–18]. Here we surveyed the mutational spectrum
in individuals with autism from nonconsanguineous populations
who were selected for the high degree of homozygosity in the
genome, since high levels of homozygosity suggest distant or
cryptic shared ancestry of the parents. We identified several
patients with potentially new autism mutations, and found that a
surprising number of these mutations occurred in genes that are
regulated by neuronal depolarization.
Results/Discussion
To sort the genetic heterogeneity of autism, we used
homozygosity analysis [19] to identify a subset of patients likely
to be enriched for recessive mutations. We performed a
homozygosity-based analysis of 1000 families (5,431 individuals)
in the Autism Genetic Research Exchange (AGRE) [20] cohort.
Though most American families in this cohort are of mixed
European ancestry and share no acknowledged near ancestors, we
hypothesized that a small proportion of European-American
parents share a traceable common ancestor, or may share
common ethnic ancestry through both parental lines, which in
either case may result in homozygosity for rare recessive founder
mutations, as has been demonstrated for a host of known
Mendelian recessive diseases [21]. We identified a small subset
of ‘‘outlier’’ AGRE families (,2% of the total) in which the
affected children show runs of homozygosity totaling up to ,9%
of their genome. This low proportion of families with elevated
homozygosity is consistent with low reported rates of consanguin-
ity in the AGRE collection. Nonetheless, in the few outlier
families, rates of homozygosity are far higher than generally
observed in individuals whose parents have no common ancestry
(#1.6%), and overlap or exceed in some cases the predicted range
of homozygosity expected in offspring of first cousin parents
(6.25%) [22] (Figure 1A). The sizes of homozygous blocks in
probands from these outlier families ranged from ,5–19 cM on
average (Figure 1B), suggesting ancient shared ancestry in these
families compared to larger blocks of homozygosity seen in
consanguineous families ($20 cM) [22]. Since the AGRE dataset
provides no specific information about shared ancestry or
consanguinity between parents, we explored the level of shared
ancestry between parents, by performing tests to estimate
relatedness between individuals based on identical-by-state (IBS)
and identical-by-descent (IBD) genotype information [23,24]. We
find that for 16 families where probands had the largest amount of
homozygosity in their genomes, some of the parental pairs were
more closely related than average (Figure S1), but that parental
relatedness by itself, as analyzed by these methods, did not always
predict the degree of homozygosity in the offspring.
We performed whole exome sequencing in 16 AGRE patients,
selected because they showed the largest total proportion of their
genome homozygous (,1%–9%) of all patients in the collection.
We reasoned that some of the runs of homozygosity would contain
homozygous causative mutations. Whole exome sequencing allows
for the high-throughput, unbiased survey of all exonic variation in
a patient, including any known mutations. Sequencing was
performed using the Illumina Genome Analyzer II platform
following enrichment of exonic sequences using Agilent’s Sur-
eSelect Human Exome Kit. We obtained an average coverage of
92% at 20X (Table S1), and identified an average of 34,615 total
variants per exome (Table S2), subsequently filtering them to
identify rare, likely deleterious changes. Since we wanted to
identify rare private mutations, common variants identified by the
1000 Genomes project and dbSNP130 were filtered out, and
remaining variants were subject to an in-house bioinformatics
pipeline to annotate variants that may disrupt gene function (by
altering the coding sequence, the splice sites, or truncating the
protein). On average, 735 variants per exome were potentially
pathogenic, and out of these, 39 per genome (on average) were
homozygous (Table S2). The availability of whole exome sequence
allowed us to test each patient systematically for mutations in
known autism genes on the autosomes as well as the X
chromosome, and no inherited mutations that were predicted to
be damaging in well-documented autism genes were found in the
16 patients.
To rule out variants that arose from spontaneous cell line
artifacts, somatic mosaic mutations, or sequencing errors, we
validated all homozygous variants in all family members using
Sequenom technology. Genotyping candidate variants in the 16
probands allowed us to examine inheritance of variants as well as
segregation with disease, since many families had multiple affected
individuals as well as unaffected siblings (Figure S2). Variants that
did not validate with Sequenom genotyping despite high
sequencing depth ($100) generally occurred in regions of the
genome that were not uniquely mappable. For uniquely mapped
variants, the rate of validation correlated well with sequencing
depth (Pearson’s correlation= 0.532, P=0.001610230, t-test)
(Figure S3). Analysis of segregation further permitted us to focus
on bona fide inherited mutations as we only considered those
variants that were homozygous in the proband (by whole exome
sequencing and Sequenom confirmation), heterozygous or absent
in unaffected siblings, and transmitted from heterozygous parents.
This validation step thus eliminates any possible sequencing errors
or somatic mutations that complicate many high-throughput
sequencing studies. We overlaid the validated variants with the
result of our homozygosity analysis and further focused our
attention on that subset of variants that fell within runs of
homozygosity shared by affected siblings and absent from
unaffected siblings. This allowed us to narrow down the number
of candidate variants per exome, and for four families only 1
variant segregated with the disease (Table 1, Figure 1C). For some
families our approach did not yield any candidate recessive
variants as expected, since homozygous variants will not
necessarily be causative even in some families selected based
upon homozygosity. We then further examined the prevalence of
candidate homozygous mutations in a control population of ,700
Author Summary
Autism spectrum disorders are neurodevelopmental dis-
orders that are genetically highly heterogeneous, with no
single gene accounting for more than 1% of cases. In order
to identify recessive mutations, we selected probands from
an outbred population based on abundance of homozy-
gosity in their genomes. We interrogated the entire coding
sequences of 16 probands that had evidence of parental
shared ancestry and identified four candidate autism
genes. Furthermore, the expression of these genes was
responsive to neuronal activity. We present a strategy for
identifying candidate recessive mutations in genetically
complex disorders.
Homozygosity and Whole-Exome Analysis in Autism
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normal individuals. We were able to exclude homozygous variants
based on several criteria including: prevalence in controls, the
genes not being expressed in brain, or the genes being mutated in
other disorders (Table S3). Under this variant prioritization model
(Figure 2), candidate autism mutations were identified in four of
the 16 probands (Table 2, Figure 1C), with these candidate disease
variants falling within runs of homozygosity shared by affected
siblings and absent from unaffected siblings.
The candidate mutations identified in this study implicate
several candidate genes in autism that encode proteins involved in
small GTPase mediated signal transduction, transcriptional
regulation, and protein modification processes (Table 2). Among
the mutations we identified is a homozygous c.144 C.T change
that creates an R40C mutation in ubiquitin protein ligase E3B
(UBE3B), a member of the E3 ubiquitin-conjugating enzyme
family. UBE3B is highly expressed in the brain and may play a
role in stress response [25]. The UBE3B R40C mutation identified
in AU035204 is predicted to be damaging, was homozygous in
both affected children (monozygotic twins), heterozygous in the
parents and unaffected sibling (Figure S2), and was absent in the
homozygous state in 1344 control chromosomes. UBE3B is highly
conserved across species and belongs to the same family as
UBE3A, the gene disrupted in Angelman syndrome, a neurode-
velopmental disorder characterized by intellectual disability,
movement or balance problems, abnormal behaviors, and speech
and language impairment. Recent work has shown that experi-
ence-driven neuronal activity induces Ube3a transcription and that
it regulates excitatory synapse development and function through
targeting the key synaptic molecules Arc and Ephexin5 [26,27].
We also narrowed down the candidate genes to only one in
AU1328302. An R125C mutation in CLTCL1, encoding clathrin
heavy chain-like 1, was homozygous in both affected children,
heterozygous in the parents and unaffected sibling, and predicted
to be damaging (Table 2 and Figure S2). CLTCL1 is disrupted in a
patient with features of DiGeorge syndrome, including intellectual
disability, facial dysmorphia, long slender digits, and genital
anomalies [28]. It encodes a member of the clathrin heavy chain
family, representing a major structural component of coated pits
and vesicles involved in intracellular trafficking, which are
important to glutamate receptor turnover.
Figure 1. Homozygosity analysis in the AGRE collection. (A) A plot of the percent homozygosity in the genome of probands from the entire
AGRE collection. All affected individuals with runs of homozygosity (ROHs) .5 cM are plotted. Offspring of first cousin marriages are expected to
have 6.25% homozygosity in their genomes, while those of second cousin marriages are expected to have 1.6%. IBD: identity by descent. (B) The
average sizes of the ROHs in cM are plotted for each of the 16 AGRE samples that were sequenced. The number of the ROHs is shown in each bar.
Values are mean 6 SEM. (C) ROHs containing candidate disease variants are shared by affected individuals and absent from unaffected individuals.
Sample names are indicated on the left (Aff.Sib: affected sibling, Unaff.Sib: unaffected sibling). Homozygous SNPs are shown in red or blue and
heterozygous SNPs are shown in green. ROHs are enclosed in the dotted box. The candidate autism gene in each family is shown in navy below the
ROHs. All other genes in grey did not contain rare, potentially pathogenic variants. No whole genome SNP data is available for individual AU035203,
but we genotyped the sample for all homozygous variants identified by the whole exome sequencing of AU035204.
doi:10.1371/journal.pgen.1002635.g001
Homozygosity and Whole-Exome Analysis in Autism
PLoS Genetics | www.plosgenetics.org 3 April 2012 | Volume 8 | Issue 4 | e1002635
Since resequencing of candidate genes in a larger cohort is an
important validation step in evaluation of any candidate gene, we
screened a larger independent cohort of whole exome data from
418 autism cases and 371 controls, sequenced as part of the ARRA
Autism Sequencing Consortium. DNA from these cases and
controls underwent whole exome capture, cloning and sequencing
in the same fashion that our 16 cases did at the Broad Institute.
For all four genes, we compared the rate of mutations under a
recessive model, looking for either homozygous or compound
heterozygous mutations in cases versus controls. As a group, the 4
genes showed a higher number of recessive mutations (homozy-
gous or compound heterozygous) in cases (24/418, 5.7%)
compared to controls (11/371, 3.0%) (P=0.042, Fisher’s exact
test, one-tailed). These mutations were all missense changes and
were relatively rare, all with allele frequencies of #5% (Table 3).
One gene, CLTCL1, especially stood out compared to the other
Figure 2. A four-dimensional approach to identifying autism candidate genes. Overview of variant filtration and prioritization of whole
exome sequencing data. Results from variant validation and homozygosity analysis were combined with neuronal activity data to identify candidate
autism genes from whole exome sequence. 1000G: 1000 Genomes Project, GMCC: genomic mutation consequence calculator, ROHs: runs of
homozygosity.
doi:10.1371/journal.pgen.1002635.g002
Table 1. Whole-exome sequencing identifies rare, previously unreported homozygous variants in 16 AGRE autism patients.
Homozygous variants Validated
Patient WES Sequenom design Sequenom run Validated Segregate with disease …and in ROHs
AU070811 32 27 (84%) 22 (81%) 10 (45%) 2 1
AU035204 48 40 (83%) 34 (85%) 12 (35%) 5 4
AU081204 29 25 (86%) 20 (80%) 8 (40%) 0 0
AU075308 36 30 (83%) 23 (77%) 11 (48%) 2 1
AU1328302 38 34 (89%) 30 (88%) 15 (50%) 1 1
AU1261301 35 30 (86%) 26 (87%) 15 (58%) 0 0
AU1353302 26 23 (88%) 17 (74%) 9 (53%) 1 0
AU1252302 32 25 (78%) 21 (84%) 9 (43%) 1 0
AU037103 25 24 (96%) 18 (75%) 10 (56%) 1 1
AU1019301 53 45 (85%) 38 (84%) 15 (39%) 3 2
AU1388301 45 40 (89%) 31 (77%) 22 (71%) 0 0
AU1196301 54 49 (91%) 41 (84%) 17 (41%) 0 0
AU022203 40 37 (92%) 34 (92%) 8 (23%) 1 0
AU000504 41 29 (71%) 25 (86%) 13 (52%) 0 0
AU039903 40 33 (82%) 31 (94%) 16 (52%) 2 2
AU062504 43 36 (84%) 28 (78%) 12 (43%) 0 0
ROHs: runs of homozygosity; WES: whole exome sequence.
doi:10.1371/journal.pgen.1002635.t001
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four genes, having 17 mutations in cases versus 6 mutations in
controls (Table 3).
Genes with essential roles in synaptic plasticity have been
implicated as an important cause of autism (e.g. NRXN1, NLGN3/
4X, SHANK2/3) [29,30], and since many synaptic plasticity genes
are regulated by neuronal depolarization [11,31], we tested the
degree to which our autism candidate genes showed expression
that could be modulated by neuronal activity. We depolarized
mouse cortical neuron cultures and assayed changes in gene
expression levels. We found that four out of four of the mouse
homologs of our candidate genes are upregulated in response to
neuronal activity (UBE3B, CLTCL1/Cltc, NCKAP5L, and ZNF18/
Zkscan6) (Figure 3). This is particularly interesting because in
general only about 1000 transcripts, or about 3% of the
transcriptome, manifest such depolarization-regulated gene tran-
scription [32]. The upregulation of Ube3b in response to
depolarization resembles the activity-dependent transcription of
its close paralog Ube3a, which has well-documented roles in
synaptic plasticity [26,27]. The regulation of expression of several
potential recessive autism genes by neuronal depolarization
suggests that the candidate genes are likely to be involved in
neuronal function and/or development, and mutations in these
genes might lead to nervous system dysfunction in the context of
autism spectrum disorders (ASDs).
In the 12/16 patients for whom we did not identify homozygous
candidate mutations, we examined the mutational spectrum under
different models of inheritance. Out of an average of 696 rare,
heterozygous, and potentially deleterious variants per exome, we
identified 67 candidate compound heterozygous changes (at least
two deleterious variants in the same gene). Sequenom genotyping
validated an average of 27 of these variants, and phasing of the
resulting set in trios revealed ,4 true compound heterozygotes
with one allele inherited from each parent. Genotyping of
unaffected siblings when available reduced this number to ,2
variants per individual consistent with fully penetrant, recessive
disease (Table S4). For three patients, we narrowed down the
candidates to 1 gene and for 8 patients there were no candidate
genes with compound heterozygous variants (Table S5). Analysis
of X-linked mutations did not identify mutations in well-validated
X-linked autism genes, though 11/14 male patients carried rare
hemizygous X-linked variants, three of which occurred in genes
associated with intellectual disability (ARHGEF6, AFF2, and
OCRL). The first variant in ARHGEF6, which encodes Rac/
Cdc42 guanine nucleotide exchange factor 6, results in an I444N
mutation. The second variant in AFF2, encoding Fragile X mental
retardation 2, causes a P847A mutation that is predicted to be
benign by PolyPhen-2. The third variant disrupts a splice donor
site in OCRL (oculocerebrorenal syndrome of Lowe gene) (Table
S6). Splicing mutations in OCRL have been identified in patients
with Lowe oculocerebrorenal syndrome [33–36], characterized by
hydrophthalmia, cataract, intellectual disability, vitamin D-
resistant rickets, amino aciduria, and reduced ammonia produc-
tion by the kidney. Since patient AU1019301 is not known to
exhibit a renal phenotype or any other Lowe syndrome
phenotypes, it is unlikely that this mutation is causative of the
neurological condition of the patient. Segregation analysis showed
that these three X-linked mutations were inherited from
heterozygous mothers, confirming that they are not cell line
artifacts. Since our study design enriched for families with
potential shared inheritance, it does not permit confident
determination of the causative nature of these potential compound
heterozygous or X-linked mutations, which could only be tested by
analysis of additional cases.
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Our results illustrate both the challenges and the potential of
whole exome sequencing in an extremely genetically heteroge-
neous condition such as autism. Each exome contains large
numbers of variants that initially challenge analysis. We present a
systematic method to approach whole exome data, by filtering for
variants compatible with identity by descent, surveying preva-
lence in controls, segregation analysis, and incorporating
functional information (Figure 2). Almost all instances in which
new genetic syndromes have been identified using whole exome
or whole genome sequencing have involved families with
recessive disorders generally (Miller syndrome) [37,38] and/or
shared parental ancestry specifically (WDR62-associated cortical
malformations) [39], because the analysis of homozygous mu-
tations provides tremendous power to improve ‘‘signal to noise’’
caused by sequencing errors, spontaneous cell line mutations,
somatic mutations, etc. Hence, tracing ancestry may be an
important tool to define genetic causes in a subset of autism
patients. Our study further emphasizes the power of whole exome
and whole genome approaches in allowing a complete survey of
all potential mutations in the patient genome, and the systematic
screening of all major modes of inheritance. Recent studies have
confirmed the contribution of de novo point mutations (5–20% of
Table 3. Whole-exome screen identifies additional potential recessive mutations in the four candidate autism genes.
Gene symbol SNP Position Mutation Zygosity Cases Controls
UBE3B rs61748069 chr12: 108,420,439 S280P Homozygous 0 1
UBE3B rs61748069 chr12: 108,420,439 S280P Compound heterozygous 1 0
var_12_109948232 chr12: 108,432,615 R609C
CLTCL1 rs5748024 chr22: 17,548,288 R1620H Compound heterozygous 10 4
rs2073738 chr22: 17,550,956 V1592M
CLTCL1 rs5748024 chr22: 17,548,288 R1620H Compound heterozygous 1 0
var_22_19241688 chr22: 17,621,688 A105T
CLTCL1 rs2073738 chr22: 17,550,956 V1592M Compound heterozygous 1 0
var_22_19241688 chr22: 17,621,688 A105T
CLTCL1 var_22_19184109 chr22: 17,564,109 R1311Q Compound heterozygous 1 0
rs1060374 chr22: 17,593,033 E691K
CLTCL1 var_22_19184113 chr22: 17,564,113 E1310K Compound heterozygous 1 0
var_22_19222211 chr22: 17,602,211 E330K
CLTCL1 var_22_19187289 chr22: 17,567,289 V1277I Compound heterozygous 0 1
rs117542241 chr22: 17,578,017 N1023I
CLTCL1 rs34486244 chr22: 17,576,615 E1087K Compound heterozygous 0 1
rs45489597 chr22: 17,597,422 R574H
CLTCL1 rs35398725 chr22: 17,587,491 K941R Compound heterozygous 1 0
rs45489597 chr22: 17,597,422 R574H
CLTCL1 rs5746697 chr22: 17,610,365 K205R Compound heterozygous 1 0
var_22_19241688 chr22: 17,621,688 A105T
CLTCL1 var_22_19241688 chr22: 17,621,688 A105T Compound heterozygous 1 0
rs3747059 chr22: 17,643,214 P61L
NCKAP5L var_12_50186544 chr12: 48,472,811 S1189N Compound heterozygous 1 0
var_12_50187579 chr12: 48,473,846 A1066S
NCKAP5L var_12_50187579 chr12: 48,473,846 A1066S Homozygous 1 0
NCKAP5L var_12_50187579 chr12: 48,473,846 A1066S Compound heterozygous 0 1
rs3741554 chr12: 48,476,934 L326M
NCKAP5L rs3741554 chr12: 48,476,934 L326M Homozygous 2 0
ZNF18 rs117755721 chr17: 11,822,081 S523L Compound heterozygous 0 1
rs62621364 chr17: 11,822,223 F476L
ZNF18 rs117755721 chr17: 11,822,081 S523L Compound heterozygous 0 1
var_17_11894428 chr17: 11,835,153 P147L
ZNF18 rs62621364 chr17: 11,822,223 F476L Homozygous 0 1
ZNF18 var_17_11881611 chr17: 11,822,336 C438Y Compound heterozygous 1 0
var_17_11894428 chr17: 11,835,153 P147L
ZNF18 var_17_11894428 chr17: 11,835,153 P147L Homozygous 1 0
Summary of the results of sequence analysis of the 4 candidate autism genes in an independent cohort of 418 autism cases and 371 controls from the ARRA Autism
Sequencing Consortium. All four genes (UBE3B, CLTCL1, NCKAP5L, and ZNF18) were analyzed for recessive mutations, either homozygous or compound heterozygous.
doi:10.1371/journal.pgen.1002635.t003
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cases) [40] and de novo copy number variants (5–10% of cases)
[41] to autism.
Our data suggest a potentially important role for recessive
mutations in autism. Though our pre-selection of 16 patients for
whole exome sequencing, and our limited analysis of whole exome
data from .400 cases in the ARRA Autism Sequencing
Consortium, does not allow us to calculate the proportion of
cases likely attributable to recessive as opposed to other causes (e.g.
de novo, X-linked), our data do suggest that a systematic analysis of
recessive causes of autism would be worthwhile. Homozygous null
mutations appear to be exceedingly rare in autism, while
homozygous missense changes were found in several candidate
genes (Table 2), consistent with the possibility that some cases of
ASD may reflect hypomorphic mutations in genes that have more
severe phenotypes when completely disabled [11]. On the other
hand, compound heterozygous recessive mutations could be more
common in the outbred families represented by the AGRE.
Furthermore, we find that different patients showed candidate
mutations in different ASD candidate genes, confirming that
recessive autism genes are likely to be highly heterogeneous. On
the other hand, several of the genes we identified represent new
neuronal depolarization-dependent genes, further supporting a
role of defective synaptic transmission and neuronal plasticity in
the pathogenesis of ASD.
Finally, the approach employed here might be of value to the
dissection of other complex traits where extreme genetic
heterogeneity is suspected or confirmed. Since many neuropsy-
chiatric conditions - including schizophrenia, intellectual disability,
and epilepsy - often (albeit not exclusively) arise from loss of gene
function, it is reasonable to suppose that recessive loss of gene
function may play detectable roles in other conditions. Despite the
rich variation in the human exome, our study design and approach
to variant prioritization allowed identification of candidate autism
genes from a relatively small sample.
Materials and Methods
Subjects
Whole exome sequencing was performed on DNA samples from
the AGRE collection available at the Broad Institute. All human
studies were reviewed and approved by the institutional review
board of the Children’s Hospital Boston, the Broad Institute,
Cambridge, and the local institutions.
Homozygosity analysis
The analysis was performed using the Illumina 550 SNP
genotype data for 1000 families from the AGRE collection. The
data was obtained with permission from the AGRE [42]. Runs of
homozygosity were calculated using custom scripts, allowing for no
more than 2 consecutive heterozygous SNPs in a run and 3
heterozygous calls in every 10 consecutive SNPs. Intervals
homozygous for the same haplotype and shared by all affected
individuals were used to narrow the locus in each family.
Estimating relatedness
We used PLINK [23] to calculate the probability that one allele
is shared IBD (Z1), and we calculated IBS2*_ratio and the percent
of informative SNPs as described by Stevens et al. [24]. Briefly,
IBS2*_ratio is equal to (IBS2*)/(IBS2*+IBS0), and the percent of
informative SNPs is equal to (IBS0+IBS2*)/(IBS0+IBS1+IBS2),
where IBS0 is the total number of observations in which two
discordant homozygotes are present, and IBS2* results when two
concordant heterozygotes are compared between any pair of
individuals.
Whole-exome sequencing and data analysis
Exome enrichment was performed on 3 mg of genomic DNA,
using the SureSelect Human Exome Kit (Agilent Technologies,
Inc., Santa Clara, CA), according to the manufacturer’s protocol.
The kit covers exonic sequences of ,18,500 genes and a total of
,33 Mb of target territory. The captured, purified and amplified
library targeting the exome from each patient was sequenced on
the Illumina GA II. Paired-end sequences were obtained at a read
length of 72 bp.
High-throughput sequence analysis was performed according to
a customized bioinformatic pipeline for tracking sequence data,
aligning reads, calculating coverage, calling variants, annotating
variants with respect to functional effect, filtering out benign
variation and flagging candidate rare, pathogenic mutations.
Briefly, BWA version 0.5.7 (ref. 3) was employed to align reads to
the human genome (reference build hg18). Consensus and variant
base calls were made with SAMtools version 0.1.7 (pileup), filtered
for quality (mapping quality .10 for insertions and deletions, and
.25 for SNPs), and loaded into a MySQL database for storage
and further processing, including annotation of the predicted
consequences (noncoding, coding synonymous, coding nonsynon-
ymous or frameshift, splice site) of each variant using GMCC [43]
(Genomic mutation consequence calculator). Candidate mutations
were identified by starting with a list of all variants, removing those
present either in dbSNP130 or the 1000 Genomes Project
database, and selecting for coding nonsynonymous, frameshift or
splice site changes. Sequence data were visualized using either the
UCSC Genome Browser or the Broad Institute Integrated
Genome Viewer. All genomic base positions are presented in
reference to the human genome NCBI build 36 (hg18). The
functional effect of the mutation on the protein was assessed using
PolyPhen-2 [44].
Figure 3. Regulation of four candidate autism genes by
neuronal activity. qRT-PCR analysis of total RNA from depolarized
mouse cortical neurons stimulated with KCl for 6 hours (the dashed line
represents no KCl treatment, values are mean 6 SEM from three
independent experiments, each experiment was performed in triplicate,
***P,0.0001, **P,0.004, *P,0.04, t-test).
doi:10.1371/journal.pgen.1002635.g003
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Sequenom genotyping
Sequenom genotyping of variants in the probands and their
family members was performed on the iPLEX Gold platform at
the Broad Institute. Variants were genotyped in control individuals
also using the Sequenom iPLEX Gold assay at the Molecular
Genetics Core Facility at Children’s Hospital Boston. The controls
collection consisted of 704 neurologically normal samples obtained
from the Coriell Cell Repositories (Camden, NJ; 584 Caucasian
samples), or available in our lab (80 Saudi and 40 Bedouin
samples).
Resequencing analysis of candidate genes in the ARRA
Autism Sequencing Consortium
We screened whole exome sequencing data from a total of 789
exomes (418 autism cases and 371 controls) that were sequenced at
the Broad Institute (as described above) as part of a case-control
study by the ARRA Autism Sequencing Consortium. Recessive
mutations (homozygous and compound heterozygous) were
counted in cases and in controls and a Fisher’s exact test was
used to determine whether the number of mutations in cases was
significantly different than the number in controls. Samples in this
study are of European ancestry from the AGRE collection, the
Autism Sequencing Consortium (ASC), and the National Institute
of Mental Health (NIMH).
Mouse cortical cultures
E16.5 C57B6 mouse embryo cortices were dissected and then
dissociated in 16Hank’s Balanced Salt Solution (HBSS), 20 mg/
ml trypsin (Worthington Biochemicals, Lakewood, NJ), and
0.32 mg/ml L-cysteine (Sigma, St. Louis, MO) for 10 minutes.
Trypsin treatment was terminated with three two-minute washes
in 16HBSS with 10 mg/ml trypsin inhibitor (Sigma, St. Louis,
MO). Trituration of cells was performed with a flame-narrowed
Pasteur pipette to fully dissociate cells. Neurons were seeded at an
approximate density of 16106/well on 6-well culture plates. The
dishes were pre-coated overnight with poly-ornithine (30 mg/mL,
Sigma) in water, washed three times with water, and washed once
with Neurobasal Medium (Life Technologies, Carlsbad, CA)
before use. Neurons were maintained in 2 ml/well Neurobasal
Medium containing B27 Supplement (2%; Invitrogen, Carlsbad,
CA), penicillin-streptomycin (50 mg/ml penicillin, 50 U/ml strep-
tomycin, Sigma) and glutamine (1 mM, Sigma, St. Louis, MO).
Neurons were grown in vitro for 7 days. 8 ml of the medium was
replaced with 10 ml fresh warm medium on the 4th and 6th days
in vitro (DIV).
Membrane depolarization and quantitative RT–PCR
detection of activity induction
For KCl depolarization of neurons, DIV 6 neurons were
quieted overnight in 1 mMTTX and 100 mM APV, and they were
incubated for 0 or 6 hours in 55 mM KCl. Total RNA was
isolated from cultures using 1 ml Trizol/well according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA). Isolated
RNA was treated with DNAseI Amplification Grade (Invitrogen,
Carlsbad, CA) and cDNA library was synthesized by cDNA High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA). The cDNA was the source of input for quantitative
PCR, using a Step One Plus Real-Time PCR Instrument and
SYBR Green reagents (Applied Biosystems, Carlsbad, CA). The
relative expression plot was constructed using concentration values
that were normalized to corresponding tubulin concentrations.
Accession numbers
The whole exome sequence data is available online (The
National Database for Autism Research (NDAR) Collection ID:
NDARCOL0001918).
Supporting Information
Figure S1 Genetic relatedness. (A) IBS2*_ratio values versus
percent of informative SNPs are plotted for all parental pairs with
available genotype data from the AGRE collection (red +).
Parental pairs from the 16 families where probands were
sequenced are indicated (black x). Family identifiers are indicated
for some of the 16 families. The majority of these families
(AU0708, AU1328, AU0399, AU0222, AU0371, AU0352,
AU0005, AU1252, AU1019, AU1196, AU0812) cluster around
the average compared to all parental pairs, while some (AU1353,
AU0625, AU1388, AU0753) had higher IBS2*_ratio values
(particularly AU0753), indicating closer relatedness, and one
family had a lower IBS2*_ratio value (AU1261). (B) Relationship
of IBS2*_ratio to IBD=1 (Z1) estimates. Higher Z1 values
indicate closer relatedness.
(TIF)
Figure S2 Pedigrees of the 16 AGRE families. Whole exome
sequencing was performed on patients indicated with an arrow.
Shaded symbols indicate affected individuals.
(TIF)
Figure S3 The rate of validation by Sequenom genotyping
correlated with sequencing depth. Pearson’s correlation = 0.532,
P=0.001610230, t-test.
(TIF)
Table S1 Whole-exome sequencing performance. Average read
depth and coverage for each exome are presented. The transition-
to-transversion ratios (Ti/Tv) were as expected for coding
sequences.
(DOCX)
Table S2 Summary of the variants detected per proband, before
and after filtration.
(DOCX)
Table S3 List of genes that were excluded as candidate autism
genes. Homozygous variants in these genes were considered
benign either because they were not in ROHs, were prevalent in
control chromosomes, were not expressed in brain, or the genes
are mutated in other disorders. Noncanonical splice site variants
were also excluded. Brain expression information is based on
data from NIMH Transcriptional Atlas of Human Brain
Development.
(DOCX)
Table S4 Summary of compound heterozygous variants per
proband, before and after filtration. For each proband, variants
that are candidates for being compound heterozygotes were
validated. Parental genotypes were used for segregation analysis to
determine which variants are true compound heterozygotes.
(DOCX)
Table S5 Candidate autism genes that contain compound
heterozygous variants.
(DOCX)
Table S6 Hemizygous variants on the X chromosome.
(DOCX)
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